Relative Leukocyte Telomere Length and Telomerase Complex Regulatory Markers Association with Leber's Hereditary Optic Neuropathy.
Leber’s hereditary optic neuropathy (LHON)
idebenone
relative leukocyte telomere length (RLTL)
telomerase complex
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
07 Sep 2022
07 Sep 2022
Historique:
received:
22
06
2022
revised:
21
08
2022
accepted:
05
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Background and Objectives: To evaluate the association of relative leukocyte telomere length (RLTL) and telomerase complex regulatory markers with Leber’s hereditary optic neuropathy (LHON). Material and Methods: A case-control study was performed in patients with LHON (≥18 years) and healthy subjects. The diagnosis of LHON was based on a genetic blood test (next-generation sequencing with Illumina MiSeq, computer analysis: BWA2.1 Illumina BaseSpace, Alamut, and mtDNA Variant analyzer 1000 were performed) and diagnostic criteria approved by the LHON disease protocol. Statistical analysis was performed using the standard statistical software package, IBM SPSS Statistics 27. Statistically significant results were considered when p < 0.05. Results: Significantly longer RLTL was observed in LHON patients than in healthy controls (p < 0.001). RLTL was significantly longer in women and men with LOHN than in healthy women and men in the control group (p < 0.001 and p = 0.003, respectively). In the elderly group (>32 years), RLTL was statistically significantly longer in LHON patients compared with healthy subjects (p < 0.001). The GG genotype of the TERC rs12696304 polymorphism was found to be statistically significantly higher in the LHON group (p = 0.041), and the C allele in the TERC rs12696304 polymorphism was found to be statistically significantly less common in the LHON group (p < 0.001). The RLTL of LHON patients was found to be statistically significantly longer in the TERC rs12696304 polymorphism in all tested genotypes (CC, p = 0.005; CG, p = 0.008; GG, p = 0.025), TEP1 rs1760904 polymorphism in the GA genotype (p < 0.001), and TEP1 gene rs1713418 in the AA and AG genotypes (p = 0.011 and p < 0.001, respectively). Conclusions: The RLTL in LHON patients was found to be longer than in healthy subjects regardless of treatment with idebenone. The TERC rs12696304 polymorphism, of all studied polymorphisms, was the most significantly associated with changes in LHON and telomere length.
Identifiants
pubmed: 36143917
pii: medicina58091240
doi: 10.3390/medicina58091240
pmc: PMC9504758
pii:
doi:
Substances chimiques
DNA, Mitochondrial
0
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Ecotoxicol Environ Saf. 2021 Oct 15;223:112558
pubmed: 34333383
Brain. 2011 Sep;134(Pt 9):e188
pubmed: 21810891
Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):1119-23
pubmed: 20211598
Handb Exp Pharmacol. 2017;240:309-336
pubmed: 27787713
Brain. 2009 Sep;132(Pt 9):2317-26
pubmed: 19525327
Ophthalmology. 1996 Mar;103(3):504-14
pubmed: 8600429
Exp Cell Res. 1995 Sep;220(1):186-93
pubmed: 7664835
Int J Lab Hematol. 2020 Jun;42(3):316-321
pubmed: 32150348
Exp Gerontol. 2014 Mar;51:15-27
pubmed: 24365661
JAMA Oncol. 2017 May 01;3(5):636-651
pubmed: 28241208
Exp Gerontol. 2015 Oct;70:18-25
pubmed: 26255046
Curr Eye Res. 1998 Apr;17(4):403-8
pubmed: 9561832
Science. 1988 Dec 9;242(4884):1427-30
pubmed: 3201231
Surv Ophthalmol. 2010 Jul-Aug;55(4):299-334
pubmed: 20471050
Am J Hum Genet. 2003 Feb;72(2):333-9
pubmed: 12518276
J Neuroophthalmol. 2017 Dec;37(4):371-381
pubmed: 28991104
Front Biosci (Landmark Ed). 2017 Jan 1;22(1):117-127
pubmed: 27814605
Nat Genet. 2010 Mar;42(3):197-9
pubmed: 20139977
PLoS One. 2012;7(9):e45182
pubmed: 23028832
Front Neurol. 2014 Jul 31;5:141
pubmed: 25132831
Ophthalmology. 2010 Mar;117(3):623-7
pubmed: 20031228
Gut. 2012 Feb;61(2):248-54
pubmed: 21708826
J Clin Invest. 2021 Mar 15;131(6):
pubmed: 33720041
Prog Retin Eye Res. 2011 Mar;30(2):81-114
pubmed: 21112411
Curr Protoc Hum Genet. 2011 Jan;Chapter 1:Unit1.19
pubmed: 21234875
Prog Mol Biol Transl Sci. 2014;125:1-40
pubmed: 24993696
Biochim Biophys Acta Mol Basis Dis. 2020 Jun 1;1866(6):165743
pubmed: 32105823
Urol J. 2019 Feb 21;16(1):50-55
pubmed: 30120764
Curr Treat Options Neurol. 2011 Feb;13(1):109-17
pubmed: 21063922
Biomed Res Int. 2013;2013:601368
pubmed: 24455708
FEBS Lett. 1999 Jun 25;453(3):365-8
pubmed: 10405177
J Hematol Oncol. 2017 Jul 17;10(1):140
pubmed: 28716051
Gene. 2014 Jan 25;534(2):139-43
pubmed: 24269974
Science. 2015 Dec 4;350(6265):1193-8
pubmed: 26785477
Orphanet J Rare Dis. 2014 Oct 23;9:158
pubmed: 25338955
CNS Neurol Disord Drug Targets. 2017;16(8):927-935
pubmed: 28745242
Cancer Discov. 2016 Jun;6(6):584-93
pubmed: 27029895
Am J Hum Genet. 1996 Aug;59(2):481-5
pubmed: 8755941
J Med Genet. 2009 Mar;46(3):145-58
pubmed: 19001017
Handb Exp Pharmacol. 2017;240:339-376
pubmed: 28233183
Front Endocrinol (Lausanne). 2021 Mar 08;12:650922
pubmed: 33763035
Prog Retin Eye Res. 2004 Jan;23(1):53-89
pubmed: 14766317
EMBO Rep. 2019 Feb;20(2):
pubmed: 30591524
PLoS One. 2017 May 1;12(5):e0176175
pubmed: 28459868
Lancet Oncol. 2008 Nov;9(11):1048-57
pubmed: 18799354
JAMA. 2010 Jan 20;303(3):250-7
pubmed: 20085953
Ophthalmology. 2005 Jan;112(1):120-6
pubmed: 15629831
J Mol Neurosci. 2021 May;71(5):1070-1081
pubmed: 33095398
Curr Pharm Des. 2017;23(4):624-628
pubmed: 28128056
Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1370-5
pubmed: 27007794
Prostate Cancer Prostatic Dis. 2015 Dec;18(4):310-6
pubmed: 26238235
Br J Ophthalmol. 2016 Sep;100(9):1232-7
pubmed: 26614631
Invest Ophthalmol Vis Sci. 2016 Oct 01;57(13):5547-5555
pubmed: 27768793